BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.